Expression and mechanism of action of the SARI tumor suppressor in prostate cancer.
The objective of this study was to assess the expression of SARI (Suppressor of AP-1, Regulated by IFN) in prostate cancer (Pca) and explore the effects and possible mechanism of action of SARI in the occurrence and development of Pca. In the current study, the expression of SARI was detected using PCR in 40 patients with prostate cancer, 20 patients with prostatic hyperplasia, and prostate cancer cells (LNCaP. and DU145). In addition, the effects of the pro-inflammatory cytokine interferon (IFN)-β on the expression of SARI in DU145 prostate cancer cells and the possible potential signaling pathways activated by SARI were detected using RT-PCR. The expression of SARI protein was downregulated from 0.6957 ± 0.0104 to 0.1597 ± 0.0032 in prostate cancer cells compared with normal prostate tissues and cells. In addition, SARI gene expression increased from 0.0794 ± 0.0133 to 0.1232 ± 0.0162 significantly in a concentration- and time-dependent manner in DU145 cells treated with IFN-β (P<0.05). Finally, MTT assays demonstrated that DU145 cells growth slowed down, flow cytometry demonstrated that IFN-β induced apoptosis increased from 0.0343 ± 0.0039 to 0.0612 + 0.0025 in DU145 prostate cancer cells. In conclusion, the results of the current study suggest that SARI might play an important role in the occurrence and development of prostate cancer. In addition, IFN-β might inhibit the growth of prostate cancer and promote cellular apoptosis by inducing the expression of SARI.
Department of Pathology, The Third Xiangya Hospital, The Central South University Changsha, Hunan, China.
Qian
Q
Chen
Department of Pathology, The Third Xiangya Hospital, The Central South University Changsha, Hunan, China.
Yonghong
Y
Gu
Department of Pathology, The Third Xiangya Hospital, The Central South University Changsha, Hunan, China.
Binghui
B
Liu
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D050976:Basic-Leucine Zipper Transcription Factors / Q000235:genetics / Q000378:metabolism*; D015153:Blotting, Western; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016899:Interferon-beta / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D015398:Signal Transduction; D013997:Time Factors; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; D050976:Basic-Leucine Zipper Transcription Factors; C569485:Batf2 protein, human; D012333:RNA, Messenger; D025521:Tumor Suppressor Proteins; D016899:Interferon-beta
IFN-β; SARI; cancer growth suppressing gene; prostate cancer